Accessibility Menu
Guangzhou Baiyunshan Pharmaceutical logo

Guangzhou Baiyunshan Pharmaceutical(OTC) GZPHF

Current Price$2.27
Market Cap$3.80BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+1,070%
5 Year+15%
1 Year-15%
1 Month+9%
Guangzhou Baiyunshan Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 2.272026-01-05
Guangzhou Baiyunshan Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.35%USD 2.082025-12-03
1 month+9.35%USD 2.082025-12-03
3 month+0%USD 2.272025-09-02
Year to date+9.35%USD 2.082025-12-03
1 year-14.6%USD 2.662024-12-17
3 year-6.33%USD 2.432023-01-06
5 year+14.96%USD 1.982020-12-31
Since inception+1,070%USD 0.202004-10-07

Guangzhou Baiyunshan Pharmaceutical Financials at a Glance

Market Cap

$3.80BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥77.99B

Net Income (TTM)

CN¥2.93B

EPS (TTM)

$0.26

P/E Ratio

9.09

Dividend

$0.12

Beta (Volatility)

0.11 (Low)

Price

$2.27

Volume

309

Open

$2.27

Previous Close

$2.27

Daily Range

$2.27 - $2.27

52-Week Range

$2.14 - $2.64

Estimated Earnings Date

Mar 21, 2026

GZPHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Guangzhou Baiyunshan Pharmaceutical

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a diversified pharmaceutical conglomerate engaged in the research, development, manufacturing, and global distribution of a wide range of medical products. The company operates through various subsidiaries and has a significant presence in both traditional Chinese and Western pharmaceuticals.

Products and Services
  • Traditional Chinese patented medicines and Western pharmaceuticals
  • Consumer goods including health supplements and pre-packaged foods
  • Wholesale and retail of medical apparatus and instruments
Growth Outlook
  • Revenue of CNY 23.05 billion in Q1 2026, showing strong demand
  • Net income of CNY 1.77 billion in Q1 2026, indicating profitability
  • Expansion into international markets enhances growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 79.5 billion
  • Net profit margin of 3.75% reflects operational efficiency
  • Dividend yield of 3.94% offers attractive returns to shareholders
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that caters to various market segments. The company's focus on both traditional and modern medical products positions it well for future growth, particularly as it expands its reach beyond China. Recent financial performance indicates a robust revenue stream and profitability, which may appeal to potential investors looking for stability and growth in the healthcare sector. The company's commitment to innovation and quality in its product offerings further enhances its competitive edge in the market.
AI Generated • Jul 25, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

27,057

CEO

Hong Li, EMBA

Website

www.gybys.com.cn

Headquarters

Guangzhou, GD 510130, CN

GZPHF Financials

Key Financial Metrics (TTM)

Gross Margin

16.00%

Operating Margin

4.13%

Net Income Margin

3.75%

Return on Equity

7.70%

Return on Capital

5.16%

Return on Assets

3.28%

Earnings Yield

11.00%

Dividend Yield

5.23%

Payout Ratio

69.49%

Stock Overview

Market Cap

$3.80BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.63B

Volume

309

Avg. Volume

0

Financials (TTM)

Gross Profit

CN¥12.50B

Operating Income

CN¥3.23B

EBITDA

CN¥3.81B

Operating Cash Flow

CN¥1.91B

Capital Expenditure

-CN¥1.24B

Free Cash Flow

CN¥667.27M

Cash & ST Invst.

CN¥12.28B

Total Debt

CN¥17.04B

Guangzhou Baiyunshan Pharmaceutical Performance Analysis

Guangzhou Baiyunshan Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 10,468,293,360-1.9%
20232023-12-31CNY 10,609,871,3451.4%
20242024-12-31CNY 10,394,275,659-2.0%
20252025-12-31CNY 10,773,547,5993.6%
Guangzhou Baiyunshan Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-13.8%
Q32025-09-302.0%
Q42025-12-31-20.0%
Q12026-03-3145.8%
Guangzhou Baiyunshan Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.362.1%
20232023-12-31CNY 0.35-2.8%
20242024-12-31CNY 0.24-31.2%
20252025-12-31CNY 0.265.4%
Guangzhou Baiyunshan Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-61.6%
Q32025-09-3014.0%
Q42025-12-31-140.8%
Q12026-03-31650.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CN¥23.05B

+2.6%

Gross Profit

CN¥4.68B

+1.6%

Gross Margin

20.31%

N/A

Market Cap

$3.80BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$140.60K

N/A

Employees

27,057

N/A

Net Income

CN¥1.77B

-3.0%

EBITDA

CN¥2.14B

-8.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CN¥12.28B

-33.7%

Total Debt

CN¥17.04B

+47.6%

Accounts Receivable

CN¥26.93B

+12.2%

Inventory

CN¥12.42B

+14.8%

Long Term Debt

CN¥5.22B

+105.6%

Short Term Debt

CN¥11.81B

+31.2%

Return on Assets

3.28%

N/A

Return on Invested Capital

6.62%

N/A

Free Cash Flow

-CN¥2.32B

+43.9%

Operating Cash Flow

-CN¥2.09B

+46.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNPUFSumitomo Pharma Co., Ltd.
$8.41+0.00%
HKMPFHikma Pharmaceuticals PLC
$20.37+0.00%
HKMPYHikma Pharmaceuticals PLC
$41.27+0.00%
SHPMYShanghai Pharmaceuticals Holding Co., Ltd
$7.34+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About GZPHF

What is the current price of Guangzhou Baiyunshan Pharmaceutical?

Guangzhou Baiyunshan Pharmaceutical is trading at $2.27 per share.

What is the 52-week range for Guangzhou Baiyunshan Pharmaceutical?

Over the past 52 weeks, Guangzhou Baiyunshan Pharmaceutical has traded between $2.14 and $2.64.

How much debt does Guangzhou Baiyunshan Pharmaceutical have?

As of the most recent reporting period, Guangzhou Baiyunshan Pharmaceutical reported total debt of CN¥3.40B.

How much cash does Guangzhou Baiyunshan Pharmaceutical have on hand?

Guangzhou Baiyunshan Pharmaceutical reported CN¥1.78B in cash and cash equivalents in its most recent financial results.

What is Guangzhou Baiyunshan Pharmaceutical’s dividend yield?

Guangzhou Baiyunshan Pharmaceutical currently has a dividend yield of 5.23%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services